We are monitoring the impact of COVID-19 on North America Ophthalmology Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 1044
Share on
Share on

North America Ophthalmology Therapeutics Market Research Report – Segmented By Indication, End User and Country (The United States, Canada and Rest of North America) - Industry Analysis, Size, Share, Growth, Trends, Forecast (2021 to 2026)

Pulished: April, 2021
ID: 1044
Pages: 145

North America Ophthalmology Therapeutics Market Size (2021 to 2026)

The size of the Ophthalmology Therapeutics Market in North America was worth USD 9.06 billion in 2021. It is further estimated to be growing at a CAGR of 6.7% and worth USD 12.53 billion by 2026.

The market is showing evident potential in the mentioned forecast period. Ophthalmology deals with the treatment of eye defects and diseases. With the recent advancements in genetics and stem cell biology, the mechanisms of many ophthalmic diseases are being revealed progressively.

The growing prevalence of vision impairment drives the North American market for Ophthalmology Therapeutics. Approximately 11% of Americans aged 20 years and older suffering from diabetes had some form of visual impairment, while 3.4 million (3%) Americans aged 40 years and older are either blind or visually impaired. 1,600,000 Americans aged 50 years and above have age-related macular degeneration. Advancements in technology in medicine are also playing a key role in the growth of the market. The growing geriatric population across the continent and a rise in disposable income are other factors fuelling market growth.

However, lack of awareness about the various diseases associated with ophthalmology is a major factor restraining the market's growth. Stringent regulatory frameworks and unclear reimbursement policies are also acting as hurdles for market growth.

This research report on the North America Ophthalmology Therapeutics Market has been segmented and sub-segmented Market into the following categories:

By Indication: 

  • Glaucoma
  • Dry Eye Syndrome
  • Diabetic Retinopathy
  • Retinal Vein Occlusion
  • Age-related Macular Degeneration
  • Macular Edema
  • Allergic Conjunctivitis

By End User: 

  • Hospitals
  • Eye Clinics
  • Diagnostic Centres
  • Patients

By Country: 

  • The United States
  • Canada
  • Rest of North America

Based on geography, Within North America, the United States is the largest market for Ophthalmology Therapeutics with a share of xx%. Simultaneously, Canada is estimated to be the fastest growing with a CAGR of xx% during the forecast period. Glaucoma is the largest indication segment accounting for a share of approximately 31%, followed by AMD, with a share of 27%.

Some of the promising companies operating in the North America Ophthalmology Therapeutics Market are Pfizer Inc., Allergan Inc., Alcon Inc., Merck & co. Inc., Roche Valeant, Regeneron, Santen, Bayer, Senju, Lpath, and Eye Gate Pharmaceuticals.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Indication                              

                                5.1.1 Glaucoma

                                5.1.2 Dry Eye Syndrome

                                5.1.3 Diabetic Retinopathy         

                                5.1.4 Retinal Vein Occlusion        

                                5.1.5 Age-Related Macular Degeneration (AMD)

                                5.1.6 Macular Edema    

                                5.1.7 Allergic Conjunctivitis         

                5.2 By End User               

                                5.2.1 Hospitals  

                                5.2.2 Eye Clinics

                                5.2.3 Diagnostic Centers              

                                5.2.4 Patients   

6. Geographical Analysis                                              

                6.1 Introduction                              

                6.2 United States                            

                6.3 Canada                         

7. Pipeline Product Analysis                                        

                7.1 Overview                    

                7.2 Pipeline Development Landscape                     

                7.3 Molecular Targets in the Pipeline                      

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target               

8.Strategic Analysis                                        

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9.Market Leaders' Analysis                                          

                9.1 Allergan, Inc.                              

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 Merck & Co Inc                         

                9.3 Pfizer                            

                9.4 Roche                           

                9.5 Novartis (Alcon)                       

                9.6 Valeant                        

                9.7 Regeneron                 

                9.8 Santen                         

                9.9 Bayer                            

                9.10 Senju                          

                9.11 Lpath                          

                9.12 Eye Gate Pharmaceuticals                 

10.Competitive Landscape                                          

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11.Market Outlook & Investment Opportunities                               

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. North America Ophthalmology Therapeutics Market, By Region, From 2021 to 2026 (USD Billion)
  2. North America Ophthalmology Therapeutics Market, By Indication, From 2021 to 2026 (USD Billion)
  3. North America Glaucoma Market, By Region, From 2021 to 2026 (USD Billion)
  4. North America Dry Eye Syndrome Market, By Region, From 2021 to 2026 (USD Billion)
  5. North America Diabetic Retinopathy Market, By Region, From 2021 to 2026 (USD Billion)
  6. North America Retinal Vein Occlusion Market, By Region, From 2021 to 2026 (USD Billion)
  7. North America Age-Related Macular Degeneration (AMD) Market, By Region, From 2021 to 2026 (USD Billion)
  8. North America Macular Edema Market, By Region, From 2021 to 2026 (USD Billion)
  9. North America Allergic Conjunctivitis Market, By Region, From 2021 to 2026 (USD Billion)
  10. North America Ophthalmology Therapeutics Market, By End-User, From 2021 to 2026 (USD Billion)
  11. North America Hospitals Market, By Region, From 2021 to 2026 (USD Billion)
  12. North America Eye Clinics Market, By Region, From 2021 to 2026 (USD Billion)
  13. North America Diagnostic Centers Market, By Region, From 2021 to 2026 (USD Billion)
  14. North America Patients Market, By Region, From 2021 to 2026 (USD Billion)
  15. United States Ophthalmology Therapeutics Market, By Indication, From 2021 to 2026 (USD Billion)
  16. United States Ophthalmology Therapeutics Market, By End-User, From 2021 to 2026 (USD Billion)
  17. Canada Ophthalmology Therapeutics Market, By Indication, From 2021 to 2026 (USD Billion)
  18. Canada Ophthalmology Therapeutics Market, By End-User, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample